Proteolysis-targeting chimeras (PROTACs) is a promising strategy for treatment of various
diseases by degrading of disease-related proteins in recent years. Up to now, most …

Small molecule drugs targeting kinases have revolutionized treatment options for millions of
patients worldwide, especially in oncology. These targeted treatments have less side effects …

Proteolysis targeting chimeras (PROTACs) have been developed to be an effective
technology for targeted protein degradation. Each PROTAC contains three key components …

Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …

The non-enzymatic functions of target proteins play key roles in the regulation of various cell
signaling pathways and are closely related to numerous human diseases. However …

Targeted protein degradation (TPD) is a promising therapeutic modality that has garnered
attention in academic, industrial, and pharmaceutical research for treating diseases such as …

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that have the
capability to induce specific protein degradation. While playing a revolutionary role in …

Proteolysis targeting chimeras (PROTACs) as a novel protein degradation technology is
opening up a burgeoning field which will bring surprises to drug design and development …

There are several challenges towards the development and clinical use of small molecule
inhibitors, which are currently the main type of targeted therapies towards intracellular …

Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …